www.immupharma.com
ImmuPharma plc is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies. The Company has operations in Mulhouse, France and Basle, Switzerland. The ImmuPharma plc focuses to develop drugs to treat serious medical conditions. It has five drugs in development to treat: lupus, cancer, severe pain, highly resistant infections, such as methicillin-resistant staphylococcus aureus (MRSA) and inflammatory and allergic disorders. Its wholly owned subsidiaries include ImmuPharma (UK) Limited, which is a holding company; ImmuPharma (France) SA, which is engaged in pharmaceutical research and development, and ImmuPharma AG, which is engaged in pharmaceutical research and development.
ImmuPharma: Two directors increase holdings in firm
ImmuPharma (LON:IMM) said two non-executive directors had increased their holding in the firm by each buying shares worth almost £50,000.
Dr Franco di Muzio bought 60,950 shares at 81 pence per share yesterday (January 23) for around £49,370, said the drug discovery and development group.
Meanwhile, Dr Ajay Agrawal acquired 62,169 shares today (January 24) at 80 pence at a cost of around £49,735.
The London-based company has operations in France and Switzerland and has five drugs in development.
Last November, broker Merchant Securities started coverage on the company with a ‘buy’ recommendation and 323 pence share price target.
That valuation was based mainly on the potential of the company’s Lupuzor treatment for the auto-immune disease lupus, which has been given the regulatory green light to go into phase III clinical trials.
Shares in the company are currently trading at 80 pence each.



















